| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
Review |
School of Biochemistry and Genetics, University of Newcastle upon Tyne/Northern Genetics Service, Royal Victoria Infirmary, 19/20 Claremont Place, Newcastle upon Tyne NE2 4AA, UK
Mr Bown Nick.Bown{at}ncl.ac.uk Neuroblastoma tumour cells show complex combinations of acquired genetic aberrations, including ploidy changes, deletions of chromosome arms 1p and 11q, amplification of the MYCN oncogene, and—most frequently—gains of chromosome arm 17q. Despite intensive investigation, the fundamental role of these features in neuroblastoma initiation and progression remains to be understood. Nonetheless, great progress has been made in relating tumour genetic abnormalities to tumour behaviour and to clinical outcome; indeed, neuroblastoma provides a paradigm for the clinical importance of tumour genetic abnormalities. Knowledge of MYCN status is increasingly being used in treatment decisions for individual children, and the clinical value of 1p and 17q data as adjuncts or refinements in risk stratification is under active investigation. Reliable detection of these molecular cytogenetic features should be regarded as mandatory for all new cases at presentation.
Key Words: neuroblastoma genetics • 17q gain in neuroblastoma • neuroblastoma: 1p and MYCN • tumour genetics and prognosis
This article has been cited by other articles:
|
|
 |
|
  N. Dey, P. K. De, M. Wang, H. Zhang, E. A. Dobrota, K. A. Robertson, and D. L. Durden CSK Controls Retinoic Acid Receptor (RAR) Signaling: a RAR-c-SRC Signaling Axis Is Required for Neuritogenic Differentiation Mol. Cell. Biol., June 1, 2007; 27(11): 4179 - 4197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Haber, J. Smith, S. B. Bordow, C. Flemming, S. L. Cohn, W. B. London, G. M. Marshall, and M. D. Norris Association of High-Level MRP1 Expression With Poor Clinical Outcome in a Large Prospective Study of Primary Neuroblastoma J. Clin. Oncol., April 1, 2006; 24(10): 1546 - 1553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Maris, G. Hii, C. A. Gelfand, S. Varde, P. S. White, E. Rappaport, S. Surrey, and P. Fortina Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform Genome Res., August 1, 2005; 15(8): 1168 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Valentijn, A. Koppen, R. van Asperen, H. A. Root, F. Haneveld, and R. Versteeg Inhibition of a New Differentiation Pathway in Neuroblastoma by Copy Number Defects of N-myc, Cdc42, and nm23 Genes Cancer Res., April 15, 2005; 65(8): 3136 - 3145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vandesompele, M. Baudis, K. De Preter, N. Van Roy, P. Ambros, N. Bown, C. Brinkschmidt, H. Christiansen, V. Combaret, M. Lastowska, et al. Unequivocal Delineation of Clinicogenetic Subgroups and Development of a New Model for Improved Outcome Prediction in Neuroblastoma J. Clin. Oncol., April 1, 2005; 23(10): 2280 - 2299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Irshad, R. B. Pedley, J. Anderson, D. S. Latchman, and V. Budhram-Mahadeo The Brn-3b Transcription Factor Regulates the Growth, Behavior, and Invasiveness of Human Neuroblastoma Cells in Vitro and in Vivo J. Biol. Chem., May 14, 2004; 279(20): 21617 - 21627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Saito-Ohara, I. Imoto, J. Inoue, H. Hosoi, A. Nakagawara, T. Sugimoto, and J. Inazawa PPM1D Is a Potential Target for 17q Gain in Neuroblastoma Cancer Res., April 15, 2003; 63(8): 1876 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Cui, A. Schroering, and H.-F. Ding p53 Mediates DNA Damaging Drug-induced Apoptosis through a Caspase-9-dependent Pathway in SH-SY5Y Neuroblastoma Cells Mol. Cancer Ther., July 1, 2002; 1(9): 679 - 686. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |
